

ASX Announcement

Bisantrene shows potent anticancer activity in diverse cell and animal models of Acute Myeloid Leukemia

- Bisantrene shows potent activity in a range of patient-derived primary acute myeloid leukemia (AML) cells and in mouse models of AML
- The combination of bisantrene and decitabine exhibits robust anticancer synergy in both cell and mouse AML models
- Key cellular pathways targeted by bisantrene were identified, further supporting the use of bisantrene in combination with decitabine as a low intensity treatment for AML patients.

06 March 2024 – Race Oncology Limited (“Race”) scientists, in collaboration with researchers from the University of Newcastle (Newcastle, Australia), presented results from pre-clinical studies exploring the use of bisantrene, both as a single drug and in combination with decitabine, as a new treatment for acute myeloid leukemia (AML) at the *New Directions in Leukaemia Research* conference in Adelaide (March 4-6, 2024).

The poster presentation entitled “*Preclinical evaluation of bisantrene alone and in combination with decitabine for Acute Myeloid Leukemia*” demonstrates that bisantrene is highly effective at killing patient-derived AML cancer cells *in vitro* and *in vivo* as a single agent and showed significantly higher anticancer activity (p-value < 0.001) when used in combination with the standard of care drug, decitabine. Key cellular pathways targeted by the synergistic combination of bisantrene and decitabine were also identified in the work.

The preclinical data are highly supportive of clinical trials of Race’s new bisantrene formulation (RC220) combined with oral decitabine, as a low intensity treatment approach, for AML patients. Data from this study is expected to be submitted for publication in a high-impact peer reviewed journal in 2024.

The poster presentation is attached to this announcement.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au

